Lapatinib
- Generic Name
- Lapatinib
- Brand Names
- Tykerb, Tyverb
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26ClFN4O4S
- CAS Number
- 231277-92-2
- Unique Ingredient Identifier
- 0VUA21238F
- Background
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2...
- Indication
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- Associated Conditions
- Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-05-08
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Nancy Lin, MD
- Target Recruit Count
- 35
- Registration Number
- NCT00470847
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
- First Posted Date
- 2007-05-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Nancy Lin, MD
- Target Recruit Count
- 87
- Registration Number
- NCT00470704
- Locations
- 🇺🇸
Dana-Farber at Faulkner Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
GW572016 In Patients With Advanced Or Metastatic Breast Cancer
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 59
- Registration Number
- NCT00462956
- Locations
GSK Investigational Site
Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Professor David Cunningham
- Target Recruit Count
- 1103
- Registration Number
- NCT00450203
- Locations
- 🇬🇧
Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom
🇬🇧Huddersfield Royal Infirmary, Huddersfield, West Yorks, England, United Kingdom
🇬🇧Cumberland Infirmary, Carlisle, England, United Kingdom
Lapatinib and Bevacizumab for Metastatic Breast Cancer
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT00444535
- Locations
- 🇺🇸
Novartis Investigative Site, Sleepy Hollow, New York, United States
Brain Metastases In ErbB2-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT00437073
- Locations
- 🇸🇪
GSK Investigational Site, Uppsala, Sweden
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT00436644
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Jacksonville, Jacksonville, Florida, United States
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 121
- Registration Number
- NCT00429299
- Locations
- 🇵🇱
GSK Investigational Site, Warszawa, Poland
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 688
- Registration Number
- NCT00424255
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 92
- Registration Number
- NCT00422903
- Locations
- 🇪🇸
GSK Investigational Site, Badalona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.